Detail akcie Affymax online

Business Summary: Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Financial Summary: BRIEF: For the six months ended 30 June 2014, Affymax Inc revenues decreased 97% to $42K. Net income totaled $5.8M vs. loss of $11.7M. Revenues reflect Collaboration revenue decrease from $1.4M to $0K. Net Income reflects Other Seling and general ecpenses decrease of 92% to $1.8M (expense), Restructuring charge decrease from $15.3M (expense) to $172K (income), Other Research and Development decrease from $11.1M (expense) to $0K.